ASCO 2023 | Challenges associated with the use of off-the-shelf CAR-T products in multiple myeloma
Adam Sperling
• 4 Jun 2023
Adam Sperling, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, reflects on allogeneic and off-the-shelf CAR-T products in multiple myeloma, highlighting challenges associated with their use including higher doses of lymphodepleting therapy which increased toxicity, as well as reduced persistence resulting in decreased efficacy when compared to autologous products. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
